(Q26852581)

2

object named as

Gert Van Assche

0 references

Geert D'Haens

5

object named as

Geert D'Haens

0 references

Walter Reinisch

1

object named as

Walter Reinisch

1 reference

9

Remo Panaccione

1 reference

10

Stefan Schreiber

1 reference

7

Pierre Michetti

1 reference

11

Mark S. Silverberg

1 reference

Ragnar Befrits

3

1 reference

William Connell

4

1 reference

Subrata Ghosh

6

1 reference

Thomas Ochsenkühn

8

1 reference

Dario Sorrentino

12

1 reference

C. Janneke van der Woude

13

1 reference

Julian Panes

15

1 reference

language of work or name

1 reference

March 2012

1 reference

Journal of Crohn's and Colitis

published in

1 reference

volume

6

1 reference

issue

2

1 reference

page(s)

248-58

1 reference

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Course of ulcerative colitis: analysis of changes in disease activity over years

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

European evidence-based Consensus on the management of ulcerative colitis: Current management

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Long-term outcome after infliximab for refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

European evidenced-based consensus on reproduction in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Safety of infliximab use during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

TNF-α and the development of the neonatal immune system: implications for inhibitor use in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study).

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.001

7 January 2021

10.1016/J.CROHNS.2011.11.001

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3707700

OpenCitations bibliographic resource ID

3707700

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3707700

PubMed publication ID

22325181

1 reference